Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1872881 | 1.00 | GBA1 (0.56) | GBA1SPHK2SPHK1SIGMAR1ALDH1A1 | |
| SCHEMBL2921412 | 1.00 | GBA1 (0.56) | GBA1SPHK2SPHK1SIGMAR1ALDH1A1 | |
| SCHEMBL7576557 | 0.85 | GBA1 (0.59) | GBA1SPHK2SPHK1SIGMAR1 | |
| SCHEMBL17141385 | 0.85 | GBA1 (0.59) | GBA1SPHK2SPHK1SIGMAR1 | |
| SCHEMBL25689630 | 0.85 | SPHK1 (0.59) | GBA1SPHK2SPHK1 | |
| SCHEMBL5371008 | 0.84 | MAPT (0.50) | GBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL10130060 | 0.84 | MAPT (0.50) | GBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL15325592 | 0.84 | MAPT (0.50) | GBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL6942852 | 0.84 | MAPT (0.50) | GBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL25689636 | 0.82 | SPHK1 (0.52) | GBA1SPHK2SPHK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | GBA1 3357/4885SPHK2 1354/4885SPHK1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.